Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
Synaptogenix, Inc. (Nasdaq: SNPX) announced Dr. Daniel Alkon's presentation at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on March 29, 2022, at 2 PM ET. His talk focuses on 'Bryostatin Targets Restoration of Synaptic Wiring in Alzheimer's Degeneration.' The company is optimistic about its Phase 2b clinical trial of Bryostatin-1 for advanced Alzheimer's, supported by new peer-reviewed data indicating cognitive restoration. Synaptogenix is committed to developing therapies for neurodegenerative disorders, backed by prior studies on Bryostatin's effects on conditions like Fragile X syndrome.
- None.
- None.
NEW YORK, March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on Tuesday, March 29th at 2pm ET. The presentation is entitled, "Bryostatin Targets Restoration of Synaptic Wiring in Alzheimer's Degeneration."
Dr. Daniel Alkon, MD stated, "We are pleased to continue our discussion regarding our recently published peer reviewed article in the Journal of Alzheimer's Disease titled 'Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease in the Absence of Memantine.' This latest data offers encouragement for our ongoing National Institute of Health sponsored six-month phase 2b clinical trial of Bryostatin-1 in advanced AD patients."
More information can be found at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit.
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com .
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 clinical trial of Bryostatin-1 and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
800-811-5591
ir@synaptogen.com
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original content:https://www.prnewswire.com/news-releases/synaptogenix-to-present-at-hanson-wade-10th-annual-neurodegenerative-drug-development-summit-301512588.html
SOURCE Synaptogenix, Inc.
FAQ
What did Synaptogenix announce on March 29, 2022?
What is the focus of Dr. Alkon's presentation at the summit?
What is the significance of the new data mentioned by Synaptogenix?
What is Bryostatin-1 used to treat?
What type of company is Synaptogenix?
